GlobeStar Therapeutics Q1 2024 reports $0 net loss per share, seeking financing for Project Amethyst™ MS drug clinical trial.
GlobeStar Therapeutics, a clinical-stage pharma company, reported $0.00 net loss per share for Q1 2024. Focused on Project Amethyst™, a drug cocktail for MS neurodegeneration, they aim to arrange financing for a pharmacokinetic study, then clinically test the FDA-approved Minocycline, Fluconazole, and Atorvastatin. If successful, it could lead to regulatory clearance in India and global markets, targeting a $31.9B market.
March 28, 2024
3 Articles